A study of the safety of a new medicine (DCLL9718S) in patients with a type of blood cancer (acute myeloid leukemia)
A Study of DCLL9718S in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination With Azacitidine in Participants With Previously Untreated AML Unsuitable for Intensive Induction Chemotherapy
-
Cancer -
Leukemia
For the latest version of this information please go to www.forpatients.roche.com